(Q53114055)

English

Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.

scientific article published on 23 April 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

author name string

Lingyun Wu

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Xiao Li

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Feng Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Zheng Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Chunkang Chang

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Qi He

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

publication date

23 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

90

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

486-493

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Blinded by the Light: The Growing Complexity of p53

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Identification of a human heme exporter that is essential for erythropoiesis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Myelodysplastic Syndromes

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12105

21 January 2018

Identifiers

10.1111/EJH.12105

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23506134

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53114055&oldid=805371888"